Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

NCT05629234 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Osimertinib

Sponsor

AstraZeneca

Collaborators

[object Object]